Intelligent Bio Solutions (INBS) risk factors

57 risks, 5 new, 1 dropped, 11 reworded since the prior year. Nasdaq compliance remains a financing and liquidity risk despite the 2025 reverse split restoring the $1 minimum bid price.

53 risks, 5 new, 9 dropped, 13 reworded since the prior year. The company faces delisting risks, material weaknesses in financial controls, and a $2,172,108 payable to the Australian Government. Net loss widened to $10,568,733 for the fiscal year ended June 30, 2025. Intellectual property risks expanded due to limited foreign protections and new U.S. tax and tariff laws.

57 risks. This is an initial filing with no prior year risk factors. Risk is dominated by going concern doubts, reliance on unlaunched products, single-source suppliers, and strict regulatory and intellectual property dependencies.